Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial
November 8, 2019Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
Top Ten most popular articles on Pharmafile.com this week
November 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …
Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook
November 8, 2019Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma
Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials
November 8, 2019Medical Communications, Research and Development AstraZeneca, pharma, roxadustat
AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …
Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma
November 8, 2019Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma
Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …
AstraZeneca reveals three-pronged “large-scale” R&D initiatives in China
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China
AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the …
Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal
November 7, 2019Sales and Marketing Biogen, Samsung Bioepis, pharma
Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …
Endo President and CEO to retire, search for a successor begins
November 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Endo pharma, appointment
Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has …
Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage
November 7, 2019Research and Development Takeda, dengue, pharma
Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …
Aveo backs off on tivozanib approval after FDA calls for more conclusive data
November 6, 2019Research and Development, Sales and Marketing Aveo Oncology, FDA, pharma
Aveo Oncology has hit another hurdle in its quest for approval of its vascular endothelial growth factor receptor tyrosine kinase …
Halozyme culls staff by 55% following Phase 3 metastatic pancreas cancer failure
November 6, 2019Manufacturing and Production, Research and Development Halozyme, pharma, trial failure
Halozyme Therapeutics has announced it is to cull its workforce by more than half in the wake of the news …
Takeda to jettison non-core asset portfolio to Stada for $660 million
November 6, 2019Research and Development, Sales and Marketing Stada, Takeda, pharma
Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …
Sandoz scores FDA approval for Neulasta biosimilar Ziextenzo to treat febrile neutropenia infection
November 6, 2019Research and Development, Sales and Marketing Amgen, FDA, Neulasta, Sandoz, Ziextenzo, pharma
The FDA has authorised the availability of Sandoz’s Ziextenzo (pegfilgrastim-bmez), a biosimilar version of Amgen’s Neulasta, it has emerged. The …
FDA approves Sanofi’s quadrivalent flu vaccine for over-65s
November 6, 2019Research and Development, Sales and Marketing FDA, Fluzone, Sanofi, flu, influenza, pharma
Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for …
Redefining the value of medicines with patients at the centre
November 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma
Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …
FDA approves RedHill Biopharma’s Talicia to combat Helicobacter pylori infection
November 4, 2019Sales and Marketing FDA, RedHill Biopharma, pharma
RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole magnesium, amoxicillin and rifabutin) for …
International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition
November 4, 2019Sales and Marketing AbbVie, Humira, pharma
With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …
Donald Trump nominates Dr Stephen Hahn as next FDA Commissioner
November 4, 2019Medical Communications, Sales and Marketing Donald Trump, FDA, Ned Sharpless, President trump, Scott Gottlieb, Trump, US
The US FDA could be set to receive its next long-term Commissioner after the White House revealed President Donald Trump’s …
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
